Zobrazeno 1 - 10
of 250
pro vyhledávání: '"Shailender, Bhatia"'
Autor:
Shailender Bhatia, Paul Nghiem, Rima Kulikauskas, Candice Church, David M Koelle, Lisa Tachiki, Kimberly Smythe, Thomas Pulliam, Shira Tabachnick-Cherny, Saumya Jani, Peter H Goff, Rashmi Bhakuni, Brandon W Seaton
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Antibodies blocking programmed death (PD)-1 or its ligand (PD-L1) have revolutionized cancer care, but many patients do not experience durable benefits. Novel treatments to stimulate antitumor immunity are needed in the PD-(L)1 refractory
Externí odkaz:
https://doaj.org/article/5d97ea745ca64b74a14af5ba8a97b20b
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Merkel cell carcinoma (MCC) incidence has risen to approximately 3,000 cases annually in the USA. Although anti-programmed cell death (ligand) 1 (PD-(L)1) agents are now the first-line treatment for advanced MCC, approximately 50% of such patients do
Externí odkaz:
https://doaj.org/article/45024368004641458a844bf7bd968ac2
Autor:
Iuliia Kovalenko, Wern Lynn Ng, Yimin Geng, Yinghong Wang, Pavlos Msaouel, Shailender Bhatia, Petros Grivas, Raed Benkhadra, Omar Alhalabi
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
BackgroundCombining immune checkpoint therapy (ICT) and vascular endothelial growth factor inhibitors (VEGFi) may result in increased treatment-related and immune-related adverse events (TRAEs and irAEs) compared to ICT alone. This metanalysis was co
Externí odkaz:
https://doaj.org/article/8f899d84a5f44098932e9c01eeae5121
Autor:
Shailender Bhatia, Ramesh Rengan, Sylvia M Lee, Scott S Tykodi, Jing Zeng, Mary Redman, Peter H Goff, Kelsey K Baker
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/be0ed318d898496dbd1c082506d1fcd6
Autor:
Evan Hall, Shailender Bhatia, Joshua Veatch, Wayne Monsky, Natalie J Miller, Jacob Leary, William McCamy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/eec190efbfad45b3ac51a9fac1981070
Autor:
David Geller, Ashley Moody, Richard Carvajal, Cara Haymaker, Sunil Reddy, Jose Lutzky, Shailender Bhatia, Diwakar Davar, Bartosz Chmielowski, Theresa Medina, Eric Wehrenberg-Klee, Marlana Orloff, Rahul Sheth, Sapna P Patel, Robert Knight, Jason Laporte, Prajna Guha, Bryan Cox, Steven Katz, Paula Novelli, Joshua D Kuban, Ann-Marie Hulstine, Kamaneh Montazeri, Shaheer A Khan, Lindsay Thornton, Anthony Lucci, Vanessa Sarli, Salyna Meas, Chandra C Ghosh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/4699634df0af46c0a34fa5697092f712
Autor:
Neha Singh, BS, Erin McClure, BS, Coley Doolittle-Amieva, PA-C, Upendra Parvathaneni, MD, Shailender Bhatia, MD, Ata S. Moshiri, MD, MPH
Publikováno v:
JAAD Case Reports, Vol 36, Iss , Pp 15-17 (2023)
Externí odkaz:
https://doaj.org/article/45afbbc2fab941188ca196bfedc173c8
Autor:
Erin M. McClure, BS, Neha Singh, BS, Kim G. Abson, MD, MPH, Shailender Bhatia, MD, Heidi J. Gray, MD, Laura S. Brown, PhD, ABPP, Ata S. Moshiri, MD, MPH
Publikováno v:
JAAD Case Reports, Vol 32, Iss , Pp 15-17 (2023)
Externí odkaz:
https://doaj.org/article/1a04fc3a76b245838676aa2ad600cc6b
Autor:
Shailender Bhatia, Paul Nghiem, Alejandro Vanegas, Kristina Lachance, Lisa Tachiki, Kevin Chiu, Emily Boller, Murtuza Bharmal, S Phani Veeranki
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background Merkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine neoplasm with annual incidence rates of 0.13–1.6 cases/100,000/year worldwide as of 2018. Chemotherapy for metastatic MCC (mMCC) has high objective response rate
Externí odkaz:
https://doaj.org/article/d79eda3aab224e61afca0b4ea644373c
Autor:
Christopher A Barker, Evan J Lipson, Harriet Kluger, Brian R Gastman, Michael T Tetzlaff, Igor Puzanov, Shailender Bhatia, Paul Nghiem, Ann W Silk, Zeynep Eroglu, Sunandana Chandra, Isaac Brownell, Anna C Pavlick, David M Miller, Vernon K Sondak, Kari L Kendra, Kathryn B Bollin, Kathleen Madden, Guilherme Rabinowits, Emily S Ruiz, Edward A Tavss
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Nonmelanoma skin cancers (NMSCs) are some of the most commonly diagnosed malignancies. In general, early-stage NMSCs have favorable outcomes; however, a small subset of patients develop resistant, advanced, or metastatic disease, or aggressive subtyp
Externí odkaz:
https://doaj.org/article/2231699fe22649279195857fb8881112